Joined the Shonan Health Innovation Park membership

　FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Masahiro Morimoto; hereinafter referred to as FRONTEO) is pleased to announce that it will join the membership of Shonan Health Innovation Park (hereinafter referred to as Shonan iPark) from October 10st.

　FRONTEO provides a groundbreaking AI drug discovery support service (Drug Discovery AI Factory, hereinafter referred to as DDAIF) that uses its proprietary specialized AI "KIBIT" that utilizes its proprietary technology to discover unknown associations that have not been described in known literature information to extract unreported target genes with high disease relevance and present them along with hypotheses such as the underlying disease mechanisms. Currently, research on technologies and methodologies that allow researchers to efficiently access the information they are looking for from a huge amount of paper information is progressing, but new discoveries from known literature information still depend on the researcher's own imagination and chance. Our innovative approach in DDAIF makes it possible to realize such discontinuous discoveries scientifically and systematically.

　By joining Shonan iPark as a member and participating in the Shonan iPark life science ecosystem, we will accelerate partnerships and co-creation projects between our company and pharmaceutical companies and others, and support companies aiming to create first-in-class drugs.

■About Shonan iPark　URL:https://www.shonan-ipark.com/
Shonan iPark is Japan's first science park established by a pharmaceutical company, which was established in April 2018 when Takeda Pharmaceutical Company opened its research facility to the public. It aims to be a place where a wide range of industries and scales of industry, government and academia come together to accelerate health innovation, and has formed an ecosystem with around 4 companies and organizations (as of September 180) in fields including not only pharmaceutical companies but also next-generation medicine, cellular agriculture, AI and government.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO supports the judgment of experts in various fields who face social issues day and night through the provision of its proprietary specialized AI "KIBIT," and creates the starting point for innovation. Unlike general-purpose AI, our proprietary natural language processing technology (patented in Japan and the United States) enables high-speed and high-precision analysis without relying on the amount of training data or computing power. In addition, by utilizing patented technology that maps (visualizes the structure) the analyzed information, "KIBIT" can directly influence the insights of experts, and in recent years, KIBIT's technology has also been used in hypothesis generation and target discovery in drug discovery.
Through KIBIT's unique technology and approach, we aim to realize the philosophy of "providing solutions that do not overlook risks and opportunities buried in records, and realizing fairness in the information society." We are promoting social implementation in various fields of legal tech AI.
Founded in August 2003, listed on TSE Mothers (currently TSE Growth) on June 8, 2007. The company operates in Japan, the United States, South Korea, and Taiwan. Obtained a first-class medical device manufacturing and sales business license and registered a controlled medical device sales business. Capital: 6 yen (as of March 26, 898,618).

* FRONTEO and KIBIT are registered trademarks of FRONTEO in Japan.

Public Relations Officer, FRONTEO Inc.
Email: [email protected]
Life Science AI Division
https://lifescience.fronteo.com/contact